Hello, I’m Dr. Hocheol Shin, or “Dr. Shin.” I study feline kidney health and aging at Greycoat Research.

I earned my Ph.D. studying cancer and immunology, and I’m now building on that experience to explore how we can help cats stay healthier for longer.

In “Reading Papers with Dr. Shin,” we’ll explore research related to feline health together. We’ll look a little deeper into how things work, what the studies actually found, and what those findings might mean for our cats. I’ll explain any unfamiliar terms as we go.

Ready to open today’s paper with Lulu?

Three-Sentence Summary

1. This study grew fibroblasts obtained from feline kidneys in culture and examined their responses to a signal called TGF-β1.

2. Cells from cats with chronic kidney disease showed increased expression of fibrosis-related genes in response to this signal, and those responses were suppressed under receptor-inhibition conditions.

3. The study illustrates why evaluating an ingredient’s mechanism at Greycoat Research should begin with a specific question: in which species, in which cells, and in which measurements did a change occur?

Introduction — Taking an Observation into the Laboratory

The previous paper showed a connection: cats with more fibrosis also had different clinical test results. What should we ask next?

“Which signals are the cells involved in this scarring responding to?”

Inside a tissue, many cells and signals are active at once. Observing them is valuable, but investigating one signal’s role requires comparisons. What happens with the signal and without it? What changes when the cells’ ability to receive it is inhibited?

Today’s paper examined a way to ask those questions using cells obtained from feline kidneys.

Background — These Cells Have a Normal Job, Too

The main cell in this story is the fibroblast. Fibroblasts help produce and regulate the material that supports the spaces between cells. We met some of that material, including collagen, in the previous article.

It is tempting to think of fibroblasts simply as troublesome cells that make scars. But healthy tissues need them, too. The important question is not just whether the cells are present. It is how they behave under different conditions.

That is where a signaling protein called TGF-β1 enters the picture. Cells receive signals through receptors and adjust their internal responses.

You do not need to memorize the whole pathway. The logic of this experiment is straightforward: add a signal, measure the response, then see what changes when signal transmission is inhibited. The researchers are asking the same cells a question under different conditions.

The Study — Asking Cells from Feline Kidneys Directly

Lawson and colleagues published this study in BMC Veterinary Research in 2018.

The researchers established fibroblast cultures from postmortem kidney cortex tissue obtained from two cats assessed as having normal kidney function and three cats with chronic kidney disease. The TGF-β1 response experiments used cells from the cats with CKD.

After TGF-β1 treatment, the cells changed shape and showed increased expression of genes related to the material between cells, including collagen and fibronectin. Expression of α-SMA, a marker used to assess myofibroblast characteristics, also increased.

When the receptor inhibitor SB431542 was added alongside TGF-β1, these responses were suppressed. A response observed after adding the signal changed when the process of receiving that signal was inhibited.

Reading the Results — A Gene Response Is Not the Same as a Scar

The key here is what was measured. The gene-expression findings discussed in this study came from measuring mRNA, the messages cells produce by reading genetic information.

Think of it as looking at how strongly a cell is issuing instructions to make certain materials. More of those instructions is not the same finding as more scar tissue in an organ.

That does not make the experiment unimportant. What interests me is that a specific signal changed responses we care about in cells obtained from cats. A phenomenon observed within tissue became an experiment that could ask more directly about the role of a particular signal.

The next questions are whether changes in gene expression translate into changes in proteins, and what they mean in actual tissue. Moving from an answer in cultured cells to an answer in the whole animal takes additional steps.

A Point to Keep in Mind — The Comparison with Normal Cells Is Still Missing

Only five cats contributed tissue to the study. In particular, the researchers could not obtain enough cells from normal kidneys to carry out the same signal-response experiments.

So this paper does not establish that cells from cats with CKD are more sensitive to TGF-β1 than normal cells. That conclusion would require testing both groups under the same conditions.

The study also did not test whether treating living cats reduced scarring or improved kidney function. What it demonstrated was a response in cultured feline cells, not a treatment effect in cats with kidney disease.

Personal Thoughts — Feline Questions Need Evidence from Cats

What I appreciate about this paper is that it established a way to ask cells from feline kidneys a direct question about feline kidney biology.

Even when a signal is well studied in another species, its effects in feline cells still need to be examined. That does not make research in other species irrelevant. It means we should distinguish evidence that helps us formulate a question from evidence that answers it in cats.

That distinction also matters when evaluating ingredient mechanisms at Greycoat Research. When we read that something “inhibits this signal,” we need to look closer: which species, which cells, and which measurements? Did gene expression change in cultured cells? Did tissue damage change? Or did the condition of an actual cat change?

There may be good reasons to investigate a possibility. But that possibility cannot simply be relabeled as proven product efficacy. For me, respecting that boundary is a starting point for researching products intended for cats.

In the first article, we examined damage inside the kidney. In the second, we connected tissue changes with clinical measurements. Today, we looked at cellular responses. That brings our first group of articles, “The Kidney Behind the Numbers,” to a close.

Next time, we’ll return to the lab report. We cannot look inside a living cat’s kidneys at every visit. What more can we learn by reading SDMA alongside creatinine?

The findings discussed in this article reflect associations, mechanisms, and early translational evidence rather than confirmed efficacy in cats with kidney disease. Please consult a veterinarian before starting any supplementation protocol.

References

1. Lawson JS, Syme HM, Wheeler-Jones CPD, Elliott J. Characterisation of Feline Renal Cortical Fibroblast Cultures and Their Transcriptional Response to Transforming Growth Factor β1. BMC Veterinary Research. 2018;14:76.

About the Author

Hocheol Shin, Ph.D.

B.S./M.S./Ph.D. in Biological Sciences, KAIST (Korea Advanced Institute of Science and Technology)

Research background in cancer immunology, tumor microenvironment, and translational oncology. Currently engaged in companion animal health and longevity research.

Educational Disclaimer

This article is for educational purposes only and is not a substitute for professional veterinary advice, diagnosis, or treatment. It is not intended to diagnose, treat, cure, or prevent any disease.

Please consult your veterinarian before making changes to your cat’s diet, supplements, or care routine.